'''Oxilorphan''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (developmental code name '''<small>L</small>-BC-2605''') is an [[opioid antagonist]] of the [[morphinan]] family that was never marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA916|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=916–}}</ref> It acts as a [[mu opioid receptor|μ-opioid receptor]] (MOR) [[receptor antagonist|antagonist]] but a [[kappa opioid receptor|κ-opioid receptor]] (KOR) [[partial agonist]], and has similar effects to [[naloxone]] and around the same potency as an MOR antagonist.<ref>Pircio AW, Gylys JA. Oxilorphan (l-N-cyclopropylmethyl-3,14-dihydroxymorphinan): a new synthetic narcotic antagonist. ''Journal of Pharmacology and Experimental Therapeutics''. 1975 Apr;193(1):23-34.</ref> Oxilorphan has some weak [[partial agonist]] actions at the MOR (with [[miosis]], [[nausea]], [[dizziness]], and some [[euphoria]] observed)<ref>Sellers EM, Thakur R. Partial agonist properties and toxicity of oral oxilorphan. ''Journal of Clinical Pharmacology''. 1976 Apr;16(4):183-7.</ref><ref name="AcademicPress1974">{{cite book|title=ANNUAL REPORTS IN MED CHEMISTRY V9 PPR|url=https://books.google.com/books?id=rZBH1_7Tx6UC&pg=PA41|date=22 November 1974|publisher=Academic Press|isbn=978-0-08-058353-2|pages=41–}}</ref> and can produce [[hallucinogen]]ic/[[dissociative]] effects at sufficient doses, indicative of KOR activation.<ref>Leander JD. Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a kappa-opioid receptor. ''European Journal of Pharmacology''. 1983 Jan 21;86(3-4):467-70.</ref> It was trialed for the treatment of [[opioid addiction]], but was not developed commercially.<ref>Tennant FS Jr, Tate JA, Ruckel E. Clinical trial in post-addicts with oxilorphan (levo-BC-2605): a new narcotic antagonist. ''Drug and Alcohol Dependence''. 1976 Jun;1(5):329-37.</ref> The KOR agonist effects of oxilorphan are associated with [[dysphoria]], which combined with its hallucinogenic effects, serve to limit its clinical usefulness; indeed, many patients who experienced these side effects refused to take additional doses in clinical trials.<ref name="Dependence1975">{{cite book|author=National Research Council (U.S.). Committee on Problems of Drug Dependence|title=Problems of drug dependence|url=https://books.google.com/books?id=3aEeAQAAMAAJ|year=1975|publisher=National Academy of Sciences.}}</ref>
